Previous close | 69.42 |
Open | 69.89 |
Bid | 70.14 x 100 |
Ask | 70.33 x 300 |
Day's range | 69.28 - 70.76 |
52-week range | 51.79 - 89.91 |
Volume | |
Avg. volume | 1,087,663 |
Market cap | 11.038B |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | 50.52 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.32 (0.46%) |
Ex-dividend date | 09 Feb 2024 |
1y target est | N/A |
Bio-Techne Corporation (NASDAQ: TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.